Esperion Therapeutics’ (ESPR) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR) in a report released on Friday,Benzinga reports.

Other equities analysts have also issued research reports about the company. StockNews.com lowered Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. The Goldman Sachs Group initiated coverage on shares of Esperion Therapeutics in a research report on Wednesday, December 18th. They set a “neutral” rating and a $4.00 price target on the stock. Needham & Company LLC restated a “buy” rating and issued a $6.00 price objective on shares of Esperion Therapeutics in a report on Friday, December 13th. Finally, Cantor Fitzgerald began coverage on shares of Esperion Therapeutics in a report on Tuesday, December 17th. They set an “overweight” rating and a $8.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. According to data from MarketBeat, Esperion Therapeutics presently has a consensus rating of “Hold” and an average target price of $7.30.

Esperion Therapeutics Stock Up 7.8 %

Shares of NASDAQ ESPR opened at $2.34 on Friday. The business’s 50 day moving average is $2.46 and its two-hundred day moving average is $2.18. Esperion Therapeutics has a 52-week low of $1.58 and a 52-week high of $3.94. The firm has a market cap of $461.06 million, a price-to-earnings ratio of -3.66 and a beta of 1.03.

Institutional Trading of Esperion Therapeutics

Several hedge funds have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. grew its holdings in Esperion Therapeutics by 1.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,069,117 shares of the biopharmaceutical company’s stock worth $3,414,000 after acquiring an additional 19,588 shares in the last quarter. Eaton Financial Holdings Company LLC acquired a new position in shares of Esperion Therapeutics during the third quarter worth $73,000. Barclays PLC grew its stake in shares of Esperion Therapeutics by 99.6% during the third quarter. Barclays PLC now owns 309,671 shares of the biopharmaceutical company’s stock worth $510,000 after purchasing an additional 154,509 shares in the last quarter. Geode Capital Management LLC increased its holdings in Esperion Therapeutics by 4.1% in the third quarter. Geode Capital Management LLC now owns 4,331,314 shares of the biopharmaceutical company’s stock valued at $7,148,000 after buying an additional 171,609 shares during the last quarter. Finally, Public Employees Retirement System of Ohio acquired a new stake in Esperion Therapeutics in the third quarter valued at $606,000. Institutional investors and hedge funds own 47.39% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.